

Treatment Guidelines for COVID-19

Department of Medical Services, together with professional associations, representatives of universities' Faculty of Medicine, and academic centers conducted reviewing of current literatures including patient's treatment record and **develop treatment guidelines for COVID-19** for physicians and healthcare personnel as a guide for decision making in treatment of patient.

The treatment of COVID-19 was categorized into 3 cases (as shown in Figure 1)

1. Mild case

With no risk, recommend symptomatic treatment (no need to give antiretroviral drug)

2. Mild case in high risk group with any of the following conditions; age >60 years, lymphopenia, chronic pulmonary disease, chronic kidney disease, heart failure, obesity, cirrhosis and any immunocompromised condition, recommend the following dual therapy

- Chloroquine (250 -500 mg) per day
- Lopinavir/Ritonavir (400/100) two times per day or alternative regimens such as Darunavir/Ritonavir (900/100) once daily or Darunavir/Ritonavir (600/100) two times per day. If infiltration is found on chest x-ray within 48 hours, add Favipiravir, same as treatment of pneumonia case for 10 days.

•

3. Pneumonia case recommend three drugs combination including of

- Chloroquine (500-1000 mg) per day
- Favipiravir (200 mg) 8 tablets two times on Day1 then 3 tablets two times per day from Day 2-10 or Favipiravir 60 mg/kg of bodyweight (in patient with BMI ≥ 35 kg/m²).
- Lopinavir/Ritonavir (400/100) two times per day or alternative regimens Darunavir/Ritonavir (900/100) once daily or Darunavir/Ritonavir (600/100) two times per day.


However, potential adverse event from drugs used for treatment of COVID-19 may occur, consider adjusting the doses as appropriate base on patient's condition.

Version 1 (13032020)

For more information please visit www.dms.moph.go.th

Treatment Guidelines for Confirmed COVID-19 cases

Treatment guidelines for Confirmed COVID-19 cases (11 March 2020)



Note: Consult SMEs: <http://www.ddc.moph.go.th/viralpneumonia/>
 Adverse Event: Lopinavir/Ritonavir + Chloroquine > 10 days in CKD with hypokalemia: QT prolongation
 Darunavir/Ritonavir: diarrhea, hepatitis
 Lopinavir: nausea, vomiting

Figure 1. Treatment guideline for COVID-19 (updated 11 March 2020)

Version 1 (13012020)
 For more information please visit www.dms.moph.go.th